Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 5/20 | 0.38 |
| ▸ | CTSG | P08311 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ACHE | P22303 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2264871 | 0.79 | POLB (0.44) | ALDH1A1 | |
| SCHEMBL9194801 | 0.75 | PARP1 (0.46) | ALDH1A1ACHE | |
| SCHEMBL11104301 | 0.72 | PARP10 (0.33) | ALDH1A1 | |
| SCHEMBL831827 | 0.71 | PARP1 (0.46) | ALDH1A1 | |
| SCHEMBL833981 | 0.67 | ALDH1A1 (0.44) | ELANECTSGALDH1A1ACHE | |
| SCHEMBL30777430 | 0.67 | ALDH1A1 (0.44) | ELANECTSGALDH1A1ACHE | |
| SCHEMBL4009918 | 0.66 | MEN1 (0.43) | ALDH1A1 | |
| SCHEMBL21861870 | 0.65 | ALDH1A1 (0.50) | ELANECTSGALDH1A1 | |
| SCHEMBL215326 | 0.64 | PARP1 (0.46) | ALDH1A1 | |
| SCHEMBL44351 | 0.64 | ALDH1A1 (0.62) | ELANEALDH1A1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440674-B2 | Substituted pyrimidine compounds as RAF inhibitors and methods of use | AMGEN INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-1976836-B9 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2013-02-06 | — | — | EP | disclosed |
| EP-1976836-B1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC (US) | 2012-08-22 | — | — | EP | disclosed |
| EP-2481729-A1 | Nintrogen-containing bicyclic heteroaryl compounds for the treatment of RAF protein kinase-mediated diseases | Amgen Inc. (US) | 2012-08-01 | — | — | EP | disclosed |
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | AMGEN INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-7989461-B2 | Substituted quinazolinamine compounds for the treatment of cancer | AMGEN INC. (US) | 2011-08-02 | — | — | US | disclosed |
| EP-1976836-A2 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | Amgen Inc. (US) | 2008-10-08 | — | — | EP | disclosed |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | AMGEN INC. | 2007-08-09 | — | — | US | disclosed |
| WO-2007076092-A2 | NITROGEN- CONTAINING BICYCLIC HETROARYL COMPOUNDS FOR THE TREATMENT OF RAF PROTEIN KINASE-MEDIATED DISEASES | AMGEN INC. (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251199-A1 | NITROGEN-CONTAINING BICYCLIC HETEROARYL COMPOUNDS AND METHODS OF USE | BRAF, RAF1, NRAS | ELANE 2211/4885CTSG 3665/4885ALDH1A1 1985/4885 |
| US-20070185324-A1 | Nitrogen-containing bicyclic heteroaryl compounds and methods of use | BRAF, NRAS, RAF1 | ELANE 2295/4885CTSG 3604/4885ALDH1A1 2020/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.